(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 June 2019 (27.06.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/120232 A8

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/CN2018/122190

(22) International Filing Date:
19 December 2018 (19.12.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/607,917 20 December 2017 (20.12.2017) US

(71) Applicant: **HARBOUR BIOMED (SHANGHAI) CO., LTD** [CN/CN]; 7th Floor, 987 Cailun Road, Zhangjiang High-Tech Park, Pudong New Area, Shanghai 201203 (CN).

(72) Inventors: **GAN, Xin**; 7th Floor, 987 Cailun Road, Zhangjiang High-Tech Park, Pudong New Area, Shanghai 201203 (CN). **HE, Yun**; 7th Floor, 987 Cailun Road, Zhangjiang High-Tech Park, Pudong New Area, Shanghai 201203 (CN). **SHEN, Yuqiang**; 7th Floor, 987 Cailun Road, Zhangjiang High-Tech Park, Pudong New Area, Shanghai 201203 (CN). **ZHAO, Jiuqiao**; 90 Bridge Street, Suite 100, Newton, Massachusetts 02458 (US). **RONG, Yiping**; 7th Floor, 987 Cailun Road, Zhangjiang High-Tech Park, Pudong New Area, Shanghai 201203 (CN). **GROSVELD, Frank**; Gerardus van, Sillevoldtstraat 29, 3065LG, Rotterdam (NL). **DRABEK, Dubravka**; Pr. Margriotlaan 67b, 3051 AR Rotterdam (NL). **VAN HAPEREN, Marinus (Rien)**; Harmonielaan 9, 4841 VK Prinsenbeek (NL). **JANSSENS, Rick**; Schietbaanlaan 106 A2, 3021LP Rotterdam (NL).

(74) Agent: **SHENZHEN SERMON PATENT FIRM**; 5B2, Building No.3, Tingwei Business Park, No.6 Liufang Rd., Xinan Avenue, Baoan District, Shenzhen, Guangdong 518152 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the identity of the inventor (Rule 4.17(i))*
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
18 March 2021 (18.03.2021)

(15) Information about Correction:
see Notice of 18 March 2021 (18.03.2021)

(54) Title: ANTIBODIES BINDING CTLA-4 AND USES THEREOF

(57) Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.

WO 2019/120232 A8